News articles tagged with "HIV"

09/11/2015 08:58:01
Jessica Stoller-Conrad
Broadly neutralizing antibodies (bNAbs) are thought to be the future for treating and preventing HIV infections. A bNAb recently characterized by Caltech researchers can neutralize HIV in different states—increasing the antibody's promise as a therapeutic.
08/16/2011 07:00:00
Katie Neith

Much like cities organize contingency plans and supplies for emergencies, chronic infectious diseases like HIV form reservoirs that ensure their survival in adverse conditions. But these reservoirs—small populations of viruses or bacteria of a specific type that persist despite attack by the immune system or drug treatment—are not always well understood. Now, however, researchers at Caltech believe they have begun to decode how a reservoir of infection can persist in HIV-positive populations.

07/29/2011 07:00:00
Kimm Fesenmaier

When it comes to a small HIV-fighting protein, called cyanovirin-N, Caltech researchers have found that two are better than one.

07/17/2011 07:00:00
Katie Neith

Each time a virus invades a healthy individual, antibodies created by the body fight to fend off the intruders. For HIV, the antibodies are very specific and are generated too slowly to combat the rapidly changing virus. However, scientists have found that some HIV-positive people develop highly potent antibodies that can neutralize different subtypes of the virus. Now, a study involving Caltech researchers points to the possibility of using these neutralizing antibodies in the development of a vaccine.


06/22/2011 06:00:00
Michael Rogers

As part of a program to foster innovative biomedical research projects, an anonymous donor has pledged $3 million each to Caltech and City of Hope to strengthen scientific collaborations between the two leading research institutions.

08/18/2010 23:00:00
Lori Oliwenstein

Two scientists from Caltech have been recognized by the National Institutes of Health for their innovative and high-impact biomedical research programs. Michael Roukes, professor of physics, applied physics, and bioengineering, and co-director of the Kavli Nanoscience Institute, and Pamela Bjorkman, Caltech's Max Delbrück Professor of Biology and a Howard Hughes Medical Institute investigator, now join the 81 Pioneers who have been selected since the program's inception in 2004.


04/02/2010 07:00:00
Lori Oliwenstein

Scientists from the Caltech have provided the first-ever glimpse of the structure of a key protein—gp120—found on the surface of a specific subgroup of the human immunodeficiency virus, HIV-1. In addition, they demonstrated that a particular antibody to gp120 makes contact not only with the protein, but with the CD4 receptor that gp120 uses to gain entrance into the body's T cells.


03/03/2010 08:00:00
Deborah Williams-Hedges

Caltech graduate student Heather D. Agnew is the recipient of the 2010 $30,000 Lemelson-MIT Caltech Student Prize. Agnew is among the four $30,000 Lemelson-MIT Collegiate Student Prize winners. She was recognized for her integral contributions to the development of innovative biochemical protocols that can be utilized for more stable, robust—and inexpensive—detection of diseases like cancer, HIV, or malaria.

04/22/2009 07:00:00
Lori Oliwenstein

Some 25 years after the AIDS epidemic spawned a worldwide search for an effective vaccine against the human immunodeficiency virus (HIV), progress in the field seems to have effectively become stalled. The reason? According to new findings from a team of researchers from Caltech, it's at least partly due to the fact that our body's natural HIV antibodies simply don't have a long enough reach to effectively neutralize the viruses they are meant to target.  

10/13/2008 07:00:00
Kathy Svitil
The transportation of antibodies from a mother to her newborn child is vital for the development of that child's nascent immune system. Those antibodies, donated by transfer across the placenta before birth or via breast milk after birth, help shape a baby's response to foreign pathogens and may influence the later occurrence of autoimmune diseases. Images from biologists at the California Institute of Technology (Caltech) have revealed for the first time the complicated process by which these antibodies are shuttled from mother's milk, through her baby's gut, and into the bloodstream, and offer new insight into the mammalian immune system.
04/21/2008 07:00:00
Jill Perry
As conventional means fail to conquer Africa's deadliest diseases-- HIV and malaria--researchers are starting to look outside the box. One solution might be Nobelist David Baltimore's novel approach to combating HIV through gene therapy. He will give the headlining lecture at the Symposium on African Health at the California Institute of Technology May 3 from 10 a.m. to 2 p.m. in Ramo Auditorium on the Caltech campus in Pasadena. Admission is free.
Subscribe to Caltech News tagged with "HIV"